R3 Stem Cell Awards

Over the past 10 years, David Greene, MD, MBA has grown R3 Stem Cell to become a world leader in regenerative therapies. And over the past few years, Awards have started to roll in!

 For the first 8 years, R3 was routinely featured in media stories from the likes of Forbes, Entrepreneur, California Business Journal, and affiliates of ABC, CBS, NBC and Fox.

 In 2020, R3 Stem Cell initially received an Award for 10 Most Innovative Companies of the Year. This was no surprise, considering the international expansion with such a cost effective offering for patients. This was followed up by an Award for 50 Smartest Companies of the Year. During the interview process for the Award, Dr. Greene was asked, “How did you come up with the idea to expand?” 

The answer from Dr. Greene was, “When our company has meetings, I make sure I’m never the smartest person in the room. We have some incredibly smart individuals at R3 whose ideas are simply stellar!” 

Another Award received in 2020 included 10 Best Companies of the Year. This Award was given based on the very high patient satisfaction, safety, growth and employee happiness. To culminate the year, R3 Stem Cell received America’s Best Regenerative Therapies Provider from Corporate Vision.

 “Considering the amount of regenerative clinics in the US, that Award means a lot to us. It’s great to be recognized as a leader in the field!” 

During an interview from one of the Award companies, Dr. Greene was asked a series of questions about R3 Stem Cell. Here is what he said:

Existing pain management therapies have been great for suppressing pain, but R3 Stem Cell is working on a fix. How are you doing this?

Most traditional medical treatments around the world are “band aids.” A classic example of this is when steroid injections are used for arthritis. They may provide relief for a couple weeks, but that’s it. Stem cell and exosome therapies approach tissue damage from arthritis, organ failure, autoimmune disease, neurologic issues, autism, CP and more from a completely opposite approach.  This is done through tissue regeneration and repair to actually work on the root of the problem. So, the procedures work tremendously well at this from several different mechanisms:

  • Cell-to-cell interactions
  • Reducing inflammation
  • Modulating the immune system
  • Promoting new blood flow
  • Reducing cell death

While stem cell therapy is not a cure for any of the conditions we treat, the technology is very safe and improves patient lives by actually repairing damage and restoring missing cells. Results often are long lasting!

How has your journey been so far?

As with any new technology that is disruptive, it has been a bumpy road that has focused on education. Helping consumers and providers understand the biologics, what they can and cannot do and what to expect has helped tremendously. Unfortunately, there are a lot of unscrupulous “players” in the industry who just look to exploit patients with suboptimal treatments while not truly caring about patient outcomes. R3 cares mostly about great outcomes and safety. With 16,000 procedures worldwide over the past decade and no significant adverse events, we are the world’s leader in regenerative therapies. Our patient satisfaction is 85% year over year, and 30% of our patient base is from referrals. The combination of great outcomes, safety, first rate patient experience and very fair pricing has propelled us to where we are now.

Usually, high-profile athletes garner all the attention when it comes to regenerative medicine. Can middle-age and elderly folks benefit from this too?

There are three demographics of individuals who can benefit from regenerative therapies. High-level athletes are definitely one of them, and of course, they generate attention because the public wants to know all about their injuries and treatment. Stem cell therapy is not a performance enhancing drug, so most sports organizations are accepting of the technology.

The second demographic is younger individuals suffering from a chronic disease like diabetes, rheumatoid arthritis, lupus, etc. But by far, the largest demographic using regenerative medicine is older individuals dealing with chronic medical conditions.

When you look at R3 Centers’ worldwide, the average age is 65. We have treated patients as old as 102! So, middle-age and elderly folks make up the vast majority of patients, and the results have been outstanding.

How does R3 Stem Cell stand apart from other regenerative therapy providers?

Most providers offering regenerative therapies simply do not take the time to understand what they are putting into patients and how to best perform the procedures. This is unfortunate, especially, when providers are asking patients to pay a considerable amount.

R3 Stem Cell provides doctors with the most important asset available with new technology – KNOWLEDGE. Our in-person and online training instills providers with accurate information to lean on when it comes to offering regenerative therapies.

In addition, R3 performs extensive marketing for patient acquisition, along with providing the best stem cell and exosome biologics available for amazing pricing. The comprehensive offering helps R3 stand apart from any other regenerative products and services company.

What does the future hold for stem cell treatments?

Existing mesenchymal stem cell therapies are working well for mitigating and improving many diseases. However, the future will allow biological cures for disease as research will eventually permit safe usage of induced pluripotent stem cells (iPSCs) in humans. This technology takes a patient’s own specialized cells and reverts them back to being pluripotent stem cells. It is not ready yet for use in humans due to safety issues, but the technology will eventually be perfected.